Latest News

Nuvalent has submitted an NDA to the FDA for neladalkib, a brain-penetrant ALK-selective TKI for pretreated advanced ALK-positive NSCLC.

A single-center study showed positive outcomes of reduced-intensity conditioning for tumor-infiltrating lymphocytes in melanoma.

Study finds risk-reducing mastectomy in BRCA1/2 carriers significantly cuts cancer risk but offers no overall survival benefit over intensive surveillance.

Learn the warning signs of renal medullary carcinoma—sickle cell trait, right-sided mass—and why INI1 testing changes therapy and survival.

FDA delays Orca‑T review as plixorafenib earns breakthrough status and ATOMIC/ASTEROID data reshape colon and lung cancer care ahead of key Q2 decisions.

FDA fast track status for CTIM-76 underscores the unmet need in platinum-resistant ovarian cancer.

Statin use alongside CD19 CAR T shows longer survival and less neurotoxicity in relapsed large B-cell lymphoma, prompting calls for trials.

Dr Mehra discussed HPV-positive oropharyngeal cancer, focusing on balancing high cure rates while minimizing toxicity through careful patient selection.

During a live event, Catherine Coombs, MD and participants explored fixed-duration frontline CLL therapies, focusing on patient selection, data gaps, and trade-offs.

The FDA granted fast track designation to PAS-004, a macrocyclic MEK inhibitor, for NF1-associated plexiform neurofibromas causing significant morbidity.

Same-day multidisciplinary clinics could shorten time to treatment, boost guideline adherence, and improve satisfaction in solid tumor care, a review finds.

Dr Dale Shepard of Cleveland Clinic discusses the PYNNACLE trial results for rezatapopt, the first successful small-molecule reactivation of mutant p53.

FDA confirms brexu-cel CAR-T for relapsed mantle cell lymphoma, citing 91% response in BTK-naive patients and updated safety guidance.

Proton therapy showed an advantage in early toxicity mitigation vs radiotherapy in patients with oropharyngeal squamous cell carcinoma.

CMS has issued a permanent billing and reimbursement J-code, J9183, for the gemcitabine intravesical system (Inlexzo) in NMIBC.

The FDA granted breakthrough therapy designation to plixorafenib for adult patients with BRAF V600E–mutated high-grade glioma, based on data from a completed phase 1/2a trial and the ongoing phase 2 FORTE basket study.

Victoria Rizk, MD, explores genomic assays to refine adjuvant therapy and capture clinical real-world evidence in breast cancer care.

The FDA has extended the deadline to review Orca-T for the treatment of myelodsyplastic syndromes and acute leukemias with a PDUFA date of July 6, 2026.

CB-011, an allogeneic CAR T product, received RMAT designation as treatment for multiple myeloma based on strong dose expansion data.

Discover the critical Q2 2026 FDA decisions for Dato-DXd in TNBC and Orca-T in blood cancers, set to transform survival outcomes and precision oncology care.

DOMMINO-1 evaluates oral triplet therapy including a new mechanism of action in relapsed/refractory multiple myeloma.

New analysis of 2304 patients shows CD19 CAR T-cell therapy efficacy is consistent across races, with outcomes driven by tumor burden and ECOG status.

Explore the top regulatory actions from the FDA in oncology this past month.

The oral FGFR2 inhibitor lirafugratinib is being reviewed by the FDA for the second-line treatment of cholangiocarcinoma harboring FGFR2 alternations.

ZW191 is engineered to bind to FRα, a cell-surface protein with high expression across several tumor types.

Young US cancer survivors face outsized food, housing and transport insecurity; Medicaid expansion and targeted SDOH screening may improve survivorship.

A retrospective analysis showed 2-year survival outcomes of over 13,000 patients receiving allogeneic hematopoietic cell transplants by donor source.

This week in oncology: FDA approves relacorilant for ovarian cancer, clinical data for lung and GI cancers, and a faster thawing method for bladder cancer.

Final results from the phase 2 OVATION 2 trial show that adding IMNN-001 to standard chemotherapy significantly improves overall survival in newly diagnosed advanced ovarian cancer.

Phase 2 TBCRC049 trial results show tucatinib triplet therapy improves survival in HER2+ breast cancer patients with leptomeningeal metastasis.

ATOMIC trial: adding atezolizumab to standard adjuvant chemotherapy cuts recurrence/death risk 50% in stage III dMMR colon cancer.